[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rhinitis-allergic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rhinitis-allergic":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,41,79,91,125,146,167,191,214,234,255,271,290,315,340],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053938","efficacy-and-safety-of-ganciclovir-capsules-in-the-treatment-of-refractory-moderate-to-severe-allergic-rhinitis-100053938",false,"NCT06436534","Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","A Randomized, Double-blind, Placebo-controlled, Single-center Clinical Trial of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","Inclusion Criteria:\n\n1. Aged between 18 and 65 years.\n2. Diagnosed with moderate-to-severe perennial allergic rhinitis based on Chinese guideline for diagnosis and treatment of allergic rhinitis (2022, revision) with Allergic Rhinitis Control Test (ARCT) score \\\u003C20.\n3. Total Nasal Symptom Score (TNSS) ≥6 or at least two of the four subdomains(sneezing, rhinorrhea, nasal itching, and nasal obstruction) ≥2 at the time of both screening and randomization. And the improvement in TNSS was assessed as \\\u003C 30% at randomization compared to screening.\n4. The participant is allergic to dust mites or other perennial allergens\n5. Voluntarily participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n1. Participants with hypersensitivity to ganciclovir capsules and its excipients.\n2. Have symptoms of viral infection, fever and other systemic symptoms in the past 2 weeks.\n3. Pregnant or lactating women and participants who have pregnancy plan during the study period.\n4. Participants with severe neutropenia (absolute neutrophil count less than 0.5\\*10\\^9\u002FL) or severe thrombocytopenia (platelet count less than 2.5\\*10\\^10\u002FL).\n5. Comorbidities such as upper and lower respiratory tract infections, history of acute or chronic sinusitis, dry rhinitis, atrophic rhinitis, severe deviated septum and asthma.\n6. Participants with other severe heart, lung, liver and kidney disease.\n7. Participants who had received any live or attenuated vaccine within 4 weeks prior to baseline or intended to receive live or attenuated vaccine (or BCG treatment) during the study period or within 4 weeks after the last administration of the investigational drug product.\n8. Participants with a history of HIV infection or who test positive for HIV serology.\n9. Participants currently infected or chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV).\n10. Participants with cirrhosis and\u002For chronic hepatitis.\n11. Participants who have been diagnosed with active parasitic infections or are at high risk of developing such infections.。\n12. Participants with a known or suspected history of immunosuppression, including a history of invasive opportunistic infections (e.g., histoplasmosis, listeriosis, coccidioidomycosis, pneumosporidiosis, aspergillosis). Or participants with what researchers believe to be unusually frequent, recurring, or prolonged infections.\n13. Participants with a known history of malignancy within 5 years prior to screening.\n14. Participants with severe co-morbidities that, in the opinion of the investigator, would adversely affect their participation in this study.\n15. Participants with combined neurological or psychiatric disorders who are unable or reluctant to cooperate.\n16. Participants with disabilities prescribed by law (blind, deaf, mute, mentally challenged, mentally handicapped, etc.).\n17. Participants suspected or having a history of alcohol and drug abuse.\n18. Other participants who have been involved in other clinical trials within 3 months before the screening.\n19. The researchers consider it inappropriate to participate in this clinical trial.","ALL","18 Years","65 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn about the clinical efficacy and safety of ganciclovir (GCV) capsules in the treatment of refractory moderate-to-severe allergic rhinitis. The main questions it aims to answer are:\n\n1. Whether ganciclovir improve nasal symptoms and life quality in patients with refractory moderate-to-severe allergic rhinitis.\n2. Whether ganciclovir is safe for the treatment of allergic rhinitis.\n\nParticipants with refractory moderate-to-severe allergic rhinitis will be included in the trial based on the inclusion and exclusion criteria, and randomized into experimental and control groups.\n\nThe two groups will be treated with blinded ganciclovir capsules or placebo for two weeks, with the background therapy of mometasone furoate aqueous nasal spray. A placebo is a look-alike capsule that contains no active drug. Nasal symptom scores, nasal secretions, blood samples and adverse events will be collected during the visits.\n\nResearchers will compare the experimental and control groups to see whether ganciclovir improve symptoms and is safe for the treatment of refractory moderate-to-severe allergic rhinitis.",[27],"Rhinitis, Allergic","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2024-05-24",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":40},"100636265","phase-2-pollenvax-subcutaneous-immunotherapy-for-mugwort-pollen-induced-allergic-rhinitis-100636265","NCT07563439","PollenVax Subcutaneous Immunotherapy for Mugwort Pollen-Induced Allergic Rhinitis","A Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of PollenVax, Emulsion for Subcutaneous Injection, in Patients With Allergic Rhinitis Induced by Mugwort (Artemisia Vulgaris) Pollen","Inclusion Criteria:\n\n1. Signed and dated written informed consent prior to any study-related procedures.\n2. Age 18 to 65 years (inclusive) at the time of signing informed consent.\n3. Ability and willingness to comply with all protocol requirements, including attendance at all scheduled visits, completion of study procedures, and maintenance of a patient diary.\n4. Clinically significant symptoms of allergic rhinitis during the mugwort pollen season, for which allergen-specific immunotherapy (ASIT) is indicated in the investigator's judgment.\n5. Diagnosis of allergic rhinitis as the primary condition caused by sensitization to mugwort pollen (Artemisia vulgaris), of moderate or severe intensity, with a duration of at least 2 years, per ARIA guidelines. Comorbid mild-to-moderate well-controlled bronchial asthma (per current GINA guidelines) is permitted (ICD-10: J30.1 and\u002For J45.0).\n6. Confirmed sensitization to Artemisia vulgaris pollen and\u002For its major component Art v 1, established by at least one of the following:\n\n   * Positive skin prick test (SPT) with wheal diameter ≥3 mm compared to negative control, with adequate positive control; co-sensitization to other inhalant allergens (including ragweed) is permitted provided the mugwort reaction is the largest wheal in the tested panel and corresponds to the seasonal pattern of symptoms; AND\u002FOR\n   * Specific IgE to the above allergens by ImmunoCAP: positive result (≥Class 1), i.e., above the positivity threshold per manufacturer instructions.\n7. Physical examination findings (including body temperature, blood pressure, heart rate), laboratory and instrumental parameters without clinically significant abnormalities per investigator assessment.\n8. Negative urine pregnancy test at screening (for women of childbearing potential).\n9. Agreement to use adequate contraception from screening until 90 days after completion of study participation (for women of childbearing potential and their partners).\n10. Participants who received placebo in the Phase I PollenVax study may be enrolled if they meet all inclusion criteria of this study and had no serious adverse events related to Phase I participation.\n\nExclusion Criteria:\n\n1. Prior allergen-specific immunotherapy (ASIT) to Artemisia vulgaris pollen or any other allergen within the last 3 years.\n2. Sensitization and clinically significant symptoms caused by another inhalant allergen that, per medical history and investigator's clinical assessment, dominate over mugwort-related symptoms and may substantially confound efficacy assessment during the observation period.\n3. Severe or uncontrolled bronchial asthma, including any of the following:\n\n   * Forced expiratory volume in 1 second (FEV1) \\\u003C 70% of predicted value at screening;\n   * Clinically significant asthma symptoms despite baseline therapy;\n   * Asthma exacerbation requiring systemic corticosteroids, hospitalization, or emergency care within the last 6 months.\n4. History of life-threatening allergic reactions (including anaphylaxis, airway edema, bronchospasm, Stevens-Johnson syndrome, Lyell syndrome) or any allergic reaction to allergen-specific immunotherapy.\n5. Chronic or acute ENT disorders at screening that may substantially affect symptom assessment or safety of study participation, including active bacterial rhinosinusitis, severe polypous rhinosinusitis, or significant anatomical nasal obstruction requiring surgical treatment.\n6. Immunoglobulin therapy within 6 months prior to screening or planned during the study period.\n7. Treatment with biological agents targeting the immune system (including anti-IgE antibodies such as omalizumab, other monoclonal antibodies, or immune checkpoint inhibitors) within the last 12 months prior to screening or planned during the study.\n8. Immune system disorders, including autoimmune diseases and primary or secondary immunodeficiencies, except well-controlled autoimmune thyroiditis and uncomplicated type 1 diabetes mellitus.\n9. Severe acute or chronic inflammatory or infectious diseases in the active phase at screening.\n10. Severe, decompensated, or unstable comorbid conditions, including but not limited to:\n\n    * Severe chronic respiratory failure;\n    * Liver cirrhosis Child-Pugh class B or C;\n    * Unstable angina or clinically significant ischemic heart disease;\n    * Chronic heart failure NYHA class III-IV or decompensated stage;\n    * Uncontrolled arterial hypertension (systolic BP ≥160 mmHg and\u002For diastolic BP ≥100 mmHg) despite treatment;\n    * Clinically significant cardiac arrhythmias, including high-grade ventricular arrhythmias (Lown classification);\n    * Myocardial infarction, acute stroke, transient ischemic attack, or pulmonary embolism within 6 months prior to Visit 0, or aortic aneurysm \\>6 cm;\n    * Less than 3 months after coronary artery bypass grafting or coronary stenting;\n    * Any other condition that, in the investigator's judgment, may affect patient safety or interpretation of study results;\n    * Active malignancy of any location or malignancy within the last 5 years, except fully treated carcinoma in situ;\n    * Severe renal failure;\n    * Severe hepatic failure.\n11. Serologically confirmed infection with HIV, hepatitis B, or hepatitis C virus.\n12. Exacerbation of chronic allergic skin disease (including atopic dermatitis or generalized urticaria) at screening that may confound assessment of allergic symptoms.\n13. Clinically significant abnormalities in routine laboratory tests per investigator assessment.\n14. Alcohol, drug, or substance dependence within the past year per investigator assessment.\n15. Pregnancy or breastfeeding.\n16. Inability to discontinue beta-blocker therapy (systemic or topical) and\u002For presence of a condition where epinephrine use for anaphylaxis management is substantially limited per investigator's clinical assessment.\n17. Use of immunosuppressive agents or other medications that cannot be discontinued during the study period and may affect patient safety or efficacy assessment.\n18. Severe psychiatric or neurological disorders impairing the ability to provide informed consent or comply with protocol requirements.\n19. Legal incapacity or limited legal capacity.\n20. Factors indicating high risk of non-compliance with study procedures, including inability to attend regular visits, maintain a patient diary, or follow protocol requirements per investigator assessment.",{"count":49,"type":21},138,[51],"PHASE2","This study evaluates the effectiveness and safety of PollenVax, a subcutaneous allergen immunotherapy (SCIT) drug developed for the treatment of allergic rhinitis and asthma caused by mugwort (Artemisia vulgaris) pollen. PollenVax contains a recombinant form of Art v 1 - the major mugwort pollen allergen - combined with the adjuvant Montanide ISA-51. It is the first-in-class product of this type designed for an ultra-short treatment course.\n\nThis is a randomized, double-blind, placebo-controlled Phase II study. Participants will be adults aged 18-65 years diagnosed with moderate-to-severe mugwort pollen-induced allergic rhinitis confirmed by skin prick test and\u002For specific IgE testing. A total of 138 participants will be randomly assigned to one of three groups: placebo, PollenVax at a cumulative dose of 22 µg of recombinant Art v 1, or PollenVax at 44 µg, administered as four weekly subcutaneous injections.\n\nThe primary efficacy outcome is the Combined Symptom and Medication Score (CSMS) during the peak mugwort pollen period (PGPP). Safety and tolerability outcomes are co-primary endpoints, assessed throughout the study. Secondary outcomes include daily symptom scores, quality of life (RQLQ\u002FAQLQ), visual analogue scale for rhinoconjunctivitis discomfort, skin prick test reactivity, and immunological markers (Art v 1-specific IgE and IgG).\n\nThe study is conducted at a single clinical center (Medcenter-Rakhat, Almaty, Kazakhstan). Sponsor: Kazakh National Agrarian Research University (KazNARU).",[54],"Rhinitis Allergic",[56,57,58,59,60,61,62,63,64,65,66,67,68,69],"PollenVax","Allergen-specific immunotherapy","Subcutaneous immunotherapy","SCIT","Mugwort pollen allergy","Artemisia vulgaris","Art v 1","Recombinant allergen","Montanide ISA-51","Ultra-short immunotherapy","Combined Symptom and Medication Score","Allergic rhinitis treatment","Phase II clinical trial","Kazakhstan","2026-06-25",{"date":72,"type":32},"2026-06-29",{"date":74,"type":32},"2026-05-01",{"date":76,"type":21},"2026-11",{"name":78,"class":39},"Kazakh National Agrarian University",{"id":80,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":25,"conditions":83,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100549630",{"count":20,"type":21},[24],[27],"2025-07-06",{"date":86,"type":32},"2025-07-10",{"date":34,"type":32},{"date":89,"type":21},"2026-05",{"name":38,"class":39},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":18,"enrollmentInfo":99,"targetDuration":4,"studyType":22,"phases":101,"briefSummary":103,"conditions":104,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":124},"100431453","phase-3-efficacy-and-safety-evaluation-of-the-treatment-of-allergy-against-cupressaceae-and-grasses-100431453","NCT04898283","Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.","Prospective, Multicentre, Doubleblind, Placebo-controlled RCT to Evaluate Efficacy and Safety With SC Immunotherapy in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitised to Grasses and Cupressaceae","Inclusion Criteria:\n\n1. Written informed consent.\n2. Aged between 12 and 65, both genders\n3. Positive suggestive clinical history of intermittent or persistent moderate to severe rhinitis \u002Frhinoconjunctivitis according to ARIA classification, with or without moderate intermittent or persistent asthma,according to GEMA 5.0, due to grass and cupressaceae pollen.\n4. Subjects with a positive skin prick-test (wheal size \\>5 mm diameter) to a standardized mixed extract of grass pollen (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne) or to one of the molecular components of the mixture and to a cupressaceae extract. In addition, the largest diameter of the papules must be greater than or equal to that of the histamine.\n5. Specific IgE \\> 3,5 KU\u002FL , against grass (preferably Phleum pratense) and cupressaceae pollen (InmunoCAP® o Immulite).\n6. Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial.\n7. Women of childbearing potential participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives.\n8. Subjects capable of complying with the dosing regimen.\n9. Subjects who own a smartphone for symptom registration and medication.\n10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology.\n\nExclusion Criteria:\n\n1. Subjects with positive prick test to other aeroallergens except for sensitisation to epithelia with occasional exposure and symptoms.\n2. Subjects with positive prick test to other aeroallergens except for sensitisation to pollen noncoseasonal with cupressus or grasses.\n3. Subjects who have received prior immunotherapy in the preceding 5 years for any of the allergens tested or a cross-reactive allergen or are currently receiving immunotherapy with any allergen.\n4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n5. Subjects with severe or uncontrolled intermittent or persistent asthma, with an FEV1 \\\u003C70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis \u002F rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated.\n6. Subjects who have previously had a severe secondary reaction during the prick test diagnostic skin test.\n7. Subjects treated with beta-blockers.\n8. Clinically unstable subjects at the time of inclusion in the trial (acute asthmatic exacerbation, respiratory infection, febrile process, acute urticaria, etc.).\n9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema.\n10. Subjects who have any pathology in which adrenaline administration is contraindicated (hyperthyroidism, HTN, heart disease, etc.).\n11. Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but potentially serious and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multioperated patients, kidney disease,).\n12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n13. Subject whose condition prevents from offering cooperation and\u002F or who has severe psychiatric disorders.\n14. Subjects with a known allergy to components of the investigational medicinal product other than the allergen.\n15. Subjects with lower respiratory diseases other than asthma such as emphysema or bronchiectasis.\n16. Subjects who are direct relatives of the researchers.\n17. Pregnant or lactating women.","12 Years",{"count":100,"type":21},180,[102],"PHASE3","A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Immunotherapy in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to cupressaceae and grasses.",[27,105,106],"Rhinoconjunctivitis","Asthma, Allergic",[108,109,110,111,112,113],"Rhinitis\u002F Rhinoconjunctivitis","Mild to moderate asthma","Allergy","Immunotherapy","Grass","cupressaceae","2025-05-07",{"date":116,"type":32},"2025-05-13",{"date":118,"type":32},"2021-05-31",{"date":120,"type":21},"2026-10",{"name":122,"class":123},"Inmunotek S.L.","INDUSTRY",27,{"id":126,"slug":127,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":18,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":138,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":144,"locationsCount":145},"100395968","phase-3-efficacy-and-safety-evaluation-for-the-treatment-of-allergy-against-mites-100395968","NCT04435990","Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites","Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Clinical Trial With SCIT in Patients With Rhinitis\u002FRhinoconjunctivitis With or Without Mild to Moderate Asthma Sensitized to Dpt. and\u002For D. Farinae","MM09-SIT-023","Inclusion Criteria:\n\n* Written informed consent.\n* Age between 12 and 65, both genders.\n* Subjects with a confirmed clinical history of inhalant allergy (intermittent or persistent moderate-severe rhinitis and\u002For rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent mild-moderate controlled asthma according to the GEMA 5.0 definition) caused by allergy to Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent.\n* Subjects with a positive skin prick-test wheal size \\>5 mm higher diameter due to Dermatophagoides pteronyssinus and\u002For Dermatophagoides farinae. The positive and negative control of the test should give consistent results. The results will be valid 12 months prior to the signing of the informed consent.\n* Specific immunoglobulin E against house dust mites \\>3,5 KU\u002FmL (InmunoCAP® o Immulite), for the complete extract of Dermatophagoides pteronyssinus and \u002F or for Dermatophagoides farinae or for some of the molecular components of these allergenic sources\n* Subjects should preferably be monosensitized to the study allergens. In case of subjects sensitized to other aeroallergens, only those with the following characteristics may be included in the study:\n\n  * Subjects with positive skin test to Blomia tropicalis and Lepidoglyphus destructor, whose specific IgE values do not exceed or equal the values for the study allergens. The maximum specific IgE value for these allergens is 3.5 KU\u002FL.\n  * Subjects with positive skin tests to epithelia, as long as they present occasional exposure and symptomatology.\n  * Subjects with positive skin tests to pollens, whose specific IgE values do not exceed or equal the values of the allergens in the study and who do not present exacerbations during the pollen season. The maximum value of specific IgE for these allergens is 17.5 KU\u002FL.\n* Subjects with negative skin test for fungi\n* Women of childbearing age (from menarche) must present a urine pregnancy test with a negative result at the time of joining the trial, before the first administration of the IMP.\n* Women of childbearing age participating in the trial must agree to use an appropriate method of contraception, meaning any act, device, or medication to prevent conception or viable pregnancy, during the trial if they are sexually active.\n* Subjects with a diagnosis of asthma according to the GEMA 5.0 guideline.\n* Subjects capable of complying with the dosing regimen.\n* Subjects who own an smartphone for symptom registration and medication\n\nExclusion Criteria:\n\n* Subjects who have received previous immunotherapy in the previous 5 years to dander, fungi, and mites.\n* Subjects in whom immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n* Subjects with persistent severe or uncontrolled asthma, with an FEV1\\\u003C70% of baseline despite adequate pharmacological treatment at the time of inclusion in the trial. Also subjects with intermittent or persistent rhinitis\u002Frhinoconjunctivitis with severe symptoms in whom oral or systemic antihistamine therapy is contraindicated.\n* Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test.\n* Subjects under treatment with β-blockers.\n* Clinically unstable subjects at the time of inclusion in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.).\n* Subjects with chronic active urticaria, severe dermographism, severe atopic dermatitis, sunburn, active psoriasis with lesions in areas where skin prick test will be performed, or a history of hereditary angioedema.\n* Subjects with any other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor impairment, uncontrolled diabetes, malformations, multiple surgeries, nephropathy).\n* Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n* Subject whose condition prevents him\u002Fher from offering cooperation and\u002For who has serious mental illness.\n* Subjects with a known allergy to other components of the investigational medicinal product other than the allergen.\n* Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis.\n* Direct investigator's relatives.\n* Pregnant women or breastfeeding women.",{"count":134,"type":21},150,[102],"A double-blinded, placebo-controlled, prospective, multicenter randomized of 2 active treatment groups, compared to 1 placebo group, for the determination of the efficacy and safety of subcutaneous immunotherapy in patients with rhinitis\u002Frhinoconjunctivitis with or without asthma, sensitised to Dermatophagoides pteronyssinus and \u002For Dermatophagoides farinae.",[27,105,106],[108,109,110,111,139],"Mites",{"date":116,"type":32},{"date":142,"type":32},"2020-10-06",{"date":36,"type":21},{"name":122,"class":123},32,{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":16,"minAge":98,"maxAge":18,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":145},"100430911","phase-3-efficacy-and-safety-evaluation-for-the-treatment-of-allergy-against-grass-and-olive-pollen-100430911","NCT04891237","Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen","A Randomized, Double-Blinded, Placebo-Controlled, Prospective, Multicenter CT to Evaluate Efficacy and Safety of Subcutaneous Immunotherapy in Subjects With Rhinitis With\u002FWithout Mild to Moderate Asthma Sensitized to Olive and Grass Pollen","Inclusion Criteria:\n\n1. Subject who has signed the informed consent.\n2. Subjects of both sexes aged between 12 and 65 years.\n3. Subjects with confirmed clinical history of inhalational allergy (rhinitis and \u002F or moderate-severe intermittent or persistent rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent controlled mild-moderate asthma according to the GEMA 5.0 classification caused by grass and olive allergy. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent\n4. Subjects with a positive prick test (higher papule diameter ≥ 5 mm) to a standardized extract of pollen from grasses (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne), or one of the components of the mixture and an olive extract.\n5. Specific IgE (CAP or Immulite) against a mixture of grasses or against one of the components of the mixture of grasses, preferably Phleum pratense and olive or one of the molecular components of allergenic sources with a value \\> 3,5 KU \u002F L.\n6. Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of joining the trial.\n7. Women of childbearing potential, and men participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives.\n8. Subjects capable of complying with the dosage regimen.\n9. Subjects who have a smartphone to record symptoms and medication.\n10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \\\u003C3,5 kU\u002FL and without relevant symptomatology\n\nExclusion Criteria:\n\n1. Subjects polysensitized to other aeroallergens with the exception of epithelia with occasional exposure and symptoms\n2. Subjects polysensitized to other aeroallergens with the exception non-seasonal pollens with grasses and olive\n3. Subjects who have received prior immunotherapy in the preceding 5 years to any aeroallergens.\n4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee.\n5. Subjects with severe or uncontrolled persistent asthma, with an FEV1 \\\u003C70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis \u002F rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated.\n6. Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test.\n7. Subjects under treatment with ß-blockers.\n8. Clinically unstable subjects at the time of enrolment in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.).\n9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburns, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema.\n10. Subjects who have any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HT, heart disease, etc.).\n11. Subjects with some other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple operations, kidney disease,).\n12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies.\n13. Subject whose condition prevents him \u002F her from offering cooperation and who has severe psychiatric disorders.\n14. Subjects with a known allergy to other investigational drug components other than the allergen.\n15. Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis.\n16. Subjects who are direct relatives of the researchers.\n17. Pregnant or lactating women.",{"count":100,"type":21},[102],"Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis \u002F rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive",[27,105,106],[108,109,110,158,159],"Grasses","Olea","2025-05-05",{"date":114,"type":32},{"date":163,"type":32},"2021-06-14",{"date":165,"type":21},"2027-01",{"name":122,"class":123},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":175,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":40},"100473682","molecular-allergen-component-resolved-diagnosis-to-decide-immunotherapy-100473682","NCT05448066","Molecular Allergen Component Resolved Diagnosis to Decide Immunotherapy","Molecular Allergen Based Diagnosis Impact on Clinical Efficacy of Aeroallergen Immunotherapy- a Pragmatic Randomized Clinical Trial","CRD-AIT","Inclusion Criteria:\n\n* Individuals with medical indication for aeroallergen immunotherapy(AIT) for allergic rhinoconjunctivitis or asthma, accordingly to the AIT guidelines;\n* Over 5 years of age;\n* Evidence of IgE-sensitization (positive skin prick tests and \u002F or serum specific-IgE)\n* Patients have indication to AIT to house dust mites and\u002For grass pollen, association with other allergens is not an exclusion criteria\n\nExclusion Criteria:\n\n* Previously performed allergen immunotherapy\n* Need the use of molecular allergen diagnosis to decide treatment and diagnostic strategy","5 Years",{"count":177,"type":21},210,[24],"Allergen immunotherapy (AIT) is used for the control of allergic diseases that are not completely responsive to avoidance strategies and\u002For pharmacotherapy. It is also considered the main treatment with the potential to modify allergic disease evolution. It's efficacy and safety in allergic rhinitis and asthma is supported by large systematic reviews and is recommended as a cornerstone treatment option in allergic disease. Molecular based allergy diagnosis has greatly evolved and the knowledge of molecular allergen sensitization pattern has been used to better define the allergen extract composition of AIT. However, uncertainty remains if this strategy is related to an increase of efficacy. Regulation of allergen extracts for allergen immunotherapy are currently underway in Europe, but there is still lack of standardization of relevant allergens and important differences are seen between allergenic contents.\n\nTherefore, we aim to evaluate, in a real-life setting, the impact of using molecular-based diagnosis versus standard diagnostic tools in the efficacy of aeroallergen immunotherapy, using a pragmatic randomized controlled trial design and also to address the impact of the discrepancy between individual aeroallergen sensitization profiles and the major allergen molecular content of aeroallergen immunotherapy.",[181,27],"Asthma","2025-04-02",{"date":184,"type":32},"2025-04-06",{"date":186,"type":32},"2022-07-30",{"date":188,"type":21},"2026-06-30",{"name":190,"class":39},"Universidade do Porto",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":22,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":40},"100584532","validation-of-the-efficacy-of-air-purifiers-in-indoor-environment-and-allergic-symptoms-in-allergic-rhinitis-patients-100584532","NCT06890572","Validation of the Efficacy of Air Purifiers in Indoor Environment and Allergic Symptoms in Allergic Rhinitis Patients","Clinical Validation of the Efficacy of Air Purifiers Equipped With Harmful Gas Filters in Improving Indoor Environment and Alleviating Allergic Symptoms in Allergic Rhinitis Patients","Inclusion Criteria:\n\n* adults aged 19 to 60\n* A person with moderate-severe persistent allergic rhinitis diagnosed by an allergy specialist or otolaryngologist and maintained without any change in treatment for more than one month\n* Total nasal symptom Score ≥ 8\n* Patients with allergic rhinitis caused by indoor inhalation antigen antigens (House dust mites ± If the wheal size of the pet skin test is greater than 3mm or the concentration of specific IgE measured by ImmunoCAP ≥ 0.35 kUA\u002FL)\n* A person who spends at least 8 hours\u002Fday per week in the home where the cleaner will be installed\n* A person with a wi-fi installed in the home where the purifier will be installed\n* A person who can read and write in Korean\n* A person who fully explains the contents, decides to participate in the study according to his\u002Fher free will, and signs a written consent form approved by each agency IRB\n\nExclusion Criteria:\n\n* Patients sensitized to seasonal antigens (tree, grass or weed pollen)\n* Rhinitis patients caused by causes other than allergic rhinitis (drug rhinitis, vascular rhinitis, infectious rhinitis, etc.)\n* Anyone who has required more than 2 weeks of systemic steroid use in the last 3 months\n* A person taking antihistamines for reasons other than rhinitis (chronic urticaria, etc.)\n* Those with anatomical abnormalities that cause nasal congestion, such as non-segmental curvature and non-segmental species\n* A person who has a plan to move during the study period or is scheduled to leave where air purifiers are installed for at least five consecutive days (e.g., travel, business trip, etc.)\n* A person who has already used an air purifier within the last three months\n* Pregnant women, lactating women, persons lacking decision-making ability, persons accommodated in facilities\n* A person whose researcher is deemed unfit to participate in clinical research due to other reasons","19 Years","60 Years",{"count":201,"type":21},44,[24],"This study targets adult patients between the ages of 19 and 60 who were diagnosed with allergic rhinitis caused by indoor inhalation antigens. Patients with moderate to severe and persistent allergic rhinitis who continue to require medication such as antihistamines and nasal spray steroids for allergic rhinitis are the subjects of this study.\n\nPatients who participate in the study will install air purifiers for a certain period of time and observe the objective and subjective improvement of rhinitis symptoms. The study is conducted on two separate occasions for four weeks, and there is a two-week period between the two periods of no use of air purifiers. There are two types of air purifiers:\n\n1)It is an air purifier with a HEPA filter and a VOC filter, and 2) a fake air purifier without air cleaning function.\n\nSubjects are divided into Group A and Group B. Group A will receive a fake air purifier, and Group B will be assigned an air purifier with a HEPA + VOC collecting filter. After using the assigned air purifier for the first four weeks, you will have a period of not using it for two weeks, and then replace the air purifiers with each other and use it again for four weeks. When you first assign an air purifier, you will receive an air purifier with a certain filter It is randomly assigned without knowing whether both the researcher and the patient will receive a regular period.\n\nDuring the study period, patients need to visit three times, including when registering for the study, and the study period is screened It will take about 5 months from the end of the air purifier operation",[54],"2025-03-17",{"date":207,"type":32},"2025-03-24",{"date":209,"type":32},"2025-03-11",{"date":211,"type":21},"2025-06-20",{"name":213,"class":39},"Yonsei University",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":221,"sex":16,"minAge":198,"maxAge":199,"enrollmentInfo":222,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":225,"conditions":226,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":40},"100510110","biomarker-screening-for-immunotherapy-response-evaluation-using-microneedle-patch-in-patients-with-allergic-rhinitis-100510110","NCT05922176","Biomarker Screening for Immunotherapy Response Evaluation Using Microneedle Patch in Patients with Allergic Rhinitis","MIST","Inclusion Criteria:\n\n* A. patient group of House dust mite\n\n  1. Adult male and female patients aged 19 to 60 with allergic rhinitis caused by the antigen of the American house dust mite (It is judged that the positive for the house dust mite is MAST ≥ Class 3 or ImmunoCAP® ≥3.5 kUA\u002FL)\n  2. Moderate-severe persistent rhinitis when evaluated according to ARIA (Allergic rhinitis and its impact on asthma)\n  3. A person who has signed a written consent to participate in this clinical trial at his\u002Fher own discretion after fully explaining the purpose, contents, characteristics of the test drug, and expected adverse reactions prior to participation in the clinical trial B. Control group (Normal person)\n\n  \u003C!-- -->\n\n  1. Adults 19 years of age or older who are judged to be free from skin diseases or allergic diseases through medical examination and visual observation by a specialist\n  2. A person who agrees to provide samples derived from the human body\n  3. A person who voluntarily agreed to this study and prepared a consent form after approval of the IRB\n\nExclusion Criteria:\n\n* A. patient group of House dust mite\n\n  1. Patients who are taking drugs that may affect efficacy evaluation (but can participate if there is no change in the drug taken during the study period)\n  2. Within six months of participation in the study, other clinical trial drugs or biological equivalence test drugs, biological agents (e.g. Anti-IgE) were administered\n  3. If there is a skin disease or tattoo in the area where the medication is applied\n  4. Immunosuppressive therapy or systemic steroid therapy for acute and chronic inflammatory skin diseases\n  5. A person in charge of testing or a person in charge of testing deemed inappropriate to participate in the test due to other reasons B. Control (Normal person)\n\n  \u003C!-- -->\n\n  1. Patients with allergic diseases such as atopic dermatitis or allergic asthma and rhinitis\n  2. A person who voluntarily disagrees with this study after approval of the IRB and has not completed the consent form",true,{"count":223,"type":21},30,"OBSERVATIONAL","Allergic rhinitis is a disease in which the nasal mucous membrane overreacts to allergens, resulting in symptoms such as spasmodic and repetitive sneezing, rhinorrhea, and stuffy nose, and can be treated with immunotherapy for radical treatment. Immunotherapy treatments include subcutaneous injections, sublingual tablets, and sublingual fluids, and subcutaneous injections have the risk of anaphylaxis, the hassle of daily administration at home, and local allergic reactions. Transdermal absorption immunotherapy (DF19001) that can compensate for the shortcomings of these existing immunotherapy drugs is currently under clinical research in Korea (Severance Hospital IRB No. 4-2021-1345).\n\nImmunotherapy requires periodic monitoring, such as analyzing immunological changes through sample collection and determining the dose and cycle of administration, because the treatment period is long and individual immune responses are different. Existing methods for confirming immune responses in samples used invasive skin biopsy and blood collection methods, but in-blood evaluation indicators have the disadvantage of being ineffective as initial efficacy evaluations or predictive evaluations before treatment. In addition, skin biopsy should be performed by a specialist, and there is a disadvantage that resistance occurs because the patient's pain is accompanied, and scars or bruises may remain. Therefore, since it is a biopsy through minimal invasion compared to a tissue biopsy, the investigators would like to use a method of collecting skin samples through a microstructure (micro needle patch), a method that has little pain and no scars. Through this study, RNA is obtained from patients with house dust mite allergic rhinitis through minimally invasive skin samples, and immunotherapy response evaluation biomarkers are screened according to immunotherapy implementation, and its use as an indicator of immunotherapy prognosis in allergic diseases.",[27],"2025-03-05",{"date":209,"type":32},{"date":230,"type":32},"2023-05-22",{"date":232,"type":21},"2026-03-31",{"name":213,"class":39},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":241,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":245,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":40},"100573093","microbial-study-of-sublingual-immunotherapy-spray-in-patients-with-allergic-rhinitis-100573093","NCT06741787","Microbial Study of Sublingual Immunotherapy Spray in Patients With Allergic Rhinitis","Microbial Characterization in Patients With Allergic Rhinitis Before and After Sublingual Immunotherapy Spray","Inclusion Criteria:\n\n* Adult patients (18-65 years).\n* Patients with canis familiari\u002Ffelis domesticus\u002Falternaria alternata allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and\u002For specific IgE).\n* Patients who visited the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University and selected sublingual spray desensitization.\n\nExclusion Criteria:\n\n* Patients who refused to accept specimen and questionnaire collection.\n* Patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.",{"count":242,"type":21},100,"The incidence of allergic rhinitis (AR) in Chinese adults was reported to be as high as 24.1% and 16.8% in children. The current symptomatic treatment has the disadvantage of poor efficacy and cannot change the natural course of the disease. Allergen immunotherapy (AIT) is the only causative treatment approved by the WHO, bringing a new option to patients with allergic diseases. The quality of allergen preparations is critical to the diagnosis and treatment of the disease, emphasizing the need for standardized preparations, and AIT treatment in the early stages of the disease may change the long-term progression of the disease. Recent studies have reported that the microbiome of patients with different efficacy of desensitization therapy is different and may be correlated with the clinical symptoms of patients, but no prospective studies have been reported.",[27],"NOT_YET_RECRUITING","2024-12-18",{"date":248,"type":32},"2024-12-19",{"date":250,"type":21},"2024-12",{"date":252,"type":21},"2026-07",{"name":254,"class":39},"The First Affiliated Hospital with Nanjing Medical University",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":221,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":262,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":243,"conditions":263,"keywords":4,"overallStatus":245,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":40},"100573094","microbial-study-of-sublingual-immunotherapy-tablets-in-patients-with-allergic-rhinitis-100573094","NCT06741800","Microbial Study of Sublingual Immunotherapy Tablets in Patients With Allergic Rhinitis","Microbial Characterization in Patients With Allergic Rhinitis Before and After Sublingual Immunotherapy Tablets","Inclusion Criteria:\n\n* Adult patients (18-65 years).\n* Patients with moderate to severe dust mite allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and\u002For specific IgE).\n* Patients who visited the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University and selected sublingual tablet desensitization.\n\nExclusion Criteria:\n\n* Patients who refused to accept specimen and questionnaire collection.\n* Patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.",{"count":242,"type":21},[27],"2024-12-17",{"date":248,"type":32},{"date":267,"type":21},"2024-12-20",{"date":269,"type":21},"2032-07",{"name":254,"class":39},{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":221,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":277,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":40},"100548944","study-on-the-mechanism-of-zhenqifuzheng-in-the-treatment-of-allergic-rhinitis-based-on-intestinal-flora-and-metabolites-100548944","NCT06427577","Study on the Mechanism of ZhenQiFuZheng in the Treatment of Allergic Rhinitis Based on Intestinal Flora and Metabolites","Inclusion Criteria:\n\n* Adult patients (18-65 years).\n* Patients who visited the Department of Otolaryngology of the First Affiliated Hospital of Nanjing Medical University and are diagnosed as allergic rhinitis .\n\nExclusion Criteria:\n\n* Patients who refused to accept specimen and questionnaire collection.\n* Patients who had nasal diseases other than allergic rhinitis, such as nasal papilloma and nasal malignant tumor.",{"count":278,"type":21},40,[24],"ZhenQi FuZheng granules has been used to improve the immune function of human body, protect the bone marrow and adrenal cortex function and promote the recovery of positive function in traditional Chinese medicine care, especially with the immune imbalance diseases like post-surgery, chemotherapy and rhinitis. This project intends to establish AR（allergic rhinitis）specimen library, cell and animal model experiment, combining clinical cohort research with applied basic research, further assess the therapeutic mechanism of ZhenQiFuZheng granules in AR. We assume that ZhenQi FuZheng granules could cause the metabolic omics changes of nasal inflammatory factors and nasal secretions in AR patients, thus improving the type 2 inflammation level of allergic rhinitis.",[27],"2024-12-04",{"date":284,"type":32},"2024-12-09",{"date":286,"type":32},"2024-06-01",{"date":288,"type":21},"2028-06-01",{"name":254,"class":39},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":221,"sex":16,"minAge":175,"maxAge":297,"enrollmentInfo":298,"targetDuration":4,"studyType":224,"phases":4,"briefSummary":300,"conditions":301,"keywords":304,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":40},"100557205","the-impact-of-airway-allergic-diseases-on-childrens-and-parents-quality-of-life-100557205","NCT06535087","The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","The Impact of Airway Allergic Diseases on the Health-related Quality of Life of Children and Their Parents (Caregivers): A Prospective Controlled Study","Inclusion Criteria:\n\n1. Children:\n\n   1. Aged 5-16 years;\n   2. Diagnosed with bronchial asthma, allergic rhinitis, or both (persistent, duration ≥4 weeks) by a respiratory or allergy specialist;\n   3. Guardian has signed the informed consent form;\n   4. Able to understand and complete the questionnaire;\n   5. Outpatients or inpatients at the Pediatrics Department of Renji Hospital in Shanghai.\n2. Parents:\n\n   1. The primary caregiver of the enrolled child;\n   2. Accompanied the child to the hospital on the day of the visit;\n   3. Signed the informed consent form;\n   4. Able to understand and complete the questionnaire.\n\nExclusion Criteria:\n\n1. Children:\n\n   1. Poor compliance;\n   2. Already received specific immunotherapy at another hospital;\n   3. Unable to independently read and complete the questionnaire;\n   4. Lost to follow-up or discontinued treatment.\n2. Parents:\n\n   1. Unwilling to sign the informed consent form;\n   2. Unable to complete the questionnaire due to physical condition or educational level.","16 Years",{"count":299,"type":21},600,"This prospective observational study aims to assess the health-related quality of life (HRQoL) of 200 children (ages 5-16) with bronchial asthma, allergic rhinitis, or both, and their 200 parents, comparing 100 children receiving specific immunotherapy with 100 receiving routine treatment. Using EQ-5D-Y(EuroQol five dimensions questionnaire, youth version), disease-specific scales, and newly developed Chinese versions of EQ-5D-Y and EQ-HWB-S (EuroQol health and well-being questionnaire, short version), the study evaluates HRQoL changes over 1 and 2 years and explores the impact on caregiver burden and spillover effects. A control group of 100 healthy children and their parents will be included. Data collection involves baseline and follow-up surveys, clinical data from medical records, and statistical analyses to compare treatment effects and validate measurement tools.",[302,27,303],"Pediatric Asthma","Quality of Life",[305],"pediatric allergic disease, health-related quality of life","2024-08-01",{"date":308,"type":32},"2024-08-02",{"date":310,"type":32},"2024-07-20",{"date":312,"type":21},"2027-05-31",{"name":314,"class":39},"Wenjing Zhou",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":323,"briefSummary":324,"conditions":325,"keywords":326,"overallStatus":245,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":336,"leadSponsor":338,"locationsCount":40},"100544691","washed-microbiota-transplantation-for-allergic-rhinitis-100544691","NCT06372184","Washed Microbiota Transplantation for Allergic Rhinitis","Efficacy and Safety of Washed Microbiota Transplantation for Allergic Rhinitis: A Randomized, Double-blind, Placebo-controlled Study","Inclusion Criteria:\n\n1. Age 18-65 years old.\n2. Meets the diagnostic criteria for allergic rhinitis.\n3. rTNSS score greater than or equal to 6 points.\n4. The subject or his\u002Fher legal representative gives informed consent, fully understands the purpose of the study, is able to communicate effectively with the investigator, and comprehends and complies with the requirements set forth in the study.\n\n   \\-\n\nExclusion Criteria:\n\n1. Patients with acute nasosinusitis or upper respiratory tract infection.\n2. Patients diagnosed with chronic sinusitis, nasal septum deviation, nasal polyps, nasal tumors, and other nasal diseases or have undergone nasal surgery.\n3. Antibiotics, PPI, probiotics, and other drugs that alter gut microbiota were used in the past two weeks.\n4. Patients with poor lung function.\n5. Patients with severe liver, kidney, and heart diseases\n6. Patients with known psychiatric or neurological diseases.\n7. Patients who use antihistamines, glucocorticoids, decongestants, mast cell membrane stabilizers, leukotriene antagonists in the past two weeks.\n8. According to the judgment of the investigator, the subjects are not suitable to participate in this clinical study, or participation in this clinical study cannot guarantee the rights and interests of the subjects.\n\n   \\-",{"count":145,"type":21},[24],"Allergic rhinitis (AR) is characterized by sneezing, nasal congestion, nasal itching and nasal leakage and is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Increasing evidence showed that gut microbiota could influence the development of AR, and we found that washed microbiota transplantation (WMT) could improve nasal symptoms in clinical practice. This clinical trial aims to evaluate the efficacy and safety of WMT for AR.",[27],[327,328,329,330,331],"washed microbiota transplantation","allergic rhinitis","reflective total nasal symptom score","rhinoconjunctivitis quality of life questionnaire score","gut microbiota","2024-05-05",{"date":334,"type":32},"2024-05-07",{"date":286,"type":21},{"date":337,"type":21},"2029-10-01",{"name":339,"class":39},"The Second Hospital of Nanjing Medical University",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":346,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":348,"targetDuration":350,"studyType":224,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":245,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":40},"100541523","allergy-asthma-and-atopic-eczema-in-finland-100541523","NCT06330974","Allergy, Asthma, and Atopic Eczema in Finland","Allergy, Asthma, and Atopic Eczema in Finland - A Nationwide Study on Prevalence, Comorbidities, Treatment and Economic Burden","FinnATOPY","Inclusion\u002FExclusion Criteria ---\\> https:\u002F\u002Fwww.finnatopy.fi\u002Fmethods",{"count":349,"type":21},2000000,"7 Years","The summary is available at --\\> https:\u002F\u002Fwww.finnatopy.fi\u002Fsummary",[181,353,110,27,354,355],"Asthma in Children","Atopic Dermatitis","Allergen Immunotherapy","2024-03-19",{"date":358,"type":32},"2024-03-26",{"date":360,"type":21},"2024-10",{"date":362,"type":21},"2034-12",{"name":364,"class":39},"Tampere University"]